Chief Medical Officer Birgitte Volck to leave Sobi

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Birgitte Volck, M.D., Ph.D., Senior Vice President of Development and Chief Medical Officer (CMO) of Sobi, will leave the company to join the rare disease research group at GlaxoSmithKline as Head of R&D Rare Diseases. Birgitte will work through a six month notice period before leaving Sobi.

"We thank Birgitte for her leadership and dedication which has helped to evolve Sobi's patient oriented research and development organisation into a highly skilled international team", said Geoffrey McDonough, President and CEO of Sobi. "Birgitte joined Sobi in 2012 and has been instrumental in advancing Sobi's late stage development projects and in bringing new treatment options to people with rare diseases."

---

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations	Investor relations
Oskar Bosson, Head of Communications	Jörgen Winroth, Vice President, Head of Investor Relations
T: [phone]	T: [phone], [phone], [phone]
[e-mail]	[e-mail]

003e_BV

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1978770